Obesity is characterized by chronic low grade of systemic inflammation that develops in response to nutrient excess and plays a key role in the pathogenesis of insulin resistance. It is characterized by macrophage infiltration into adipose tissue (AT) and abnormal cytokine production. These factors damage the metabolic homeostasis leading to alteration in the insulin signaling in specific tissues and organs such as AT and liver. Thus, obese subjects develop over the time resistance to the cellular actions of insulin. Glucagon like peptide-2 (GLP-2) is an intestinal proglucagon-derived hormone released together with GLP1, in response to the passage of food by the distal small intestine. Once released, GLP-2 acts through its specific GLP-2 receptor. GLP-2 quickly is degraded with formation of GLP-2 (3-33). In order to extend the GLP-2 half-life, the protease-resistant analog, Gly2-GLP-2 (teduglutide) has been synthetized. The GLP-2 mainly influences gastrointestinal functions, but it exhibits also anti-inflammatory activity in intestinal disease models, in the brain of obese high fat diet (HFD) mice and can mitigate metabolic dysfunctions associated with hyperadiposity. The aim of the present study was to investigate if Gly2-GLP-2 exerts anti-inflammatory effects in AT and liver of HFD mice, which present central and peripheral IR, and to verify a possible improvement in the insulin signaling.

Baldassano S, A.A. (2020). Glucagon-like peptide-2 analog and inflammatory state in obese mice. ENDOCRINE [10.1007/s12020-020-02261-0].

Glucagon-like peptide-2 analog and inflammatory state in obese mice

Baldassano S;Amato A;Terzo S;Caldara Gaetano felice;Lentini L;Mule F.
2020-01-01

Abstract

Obesity is characterized by chronic low grade of systemic inflammation that develops in response to nutrient excess and plays a key role in the pathogenesis of insulin resistance. It is characterized by macrophage infiltration into adipose tissue (AT) and abnormal cytokine production. These factors damage the metabolic homeostasis leading to alteration in the insulin signaling in specific tissues and organs such as AT and liver. Thus, obese subjects develop over the time resistance to the cellular actions of insulin. Glucagon like peptide-2 (GLP-2) is an intestinal proglucagon-derived hormone released together with GLP1, in response to the passage of food by the distal small intestine. Once released, GLP-2 acts through its specific GLP-2 receptor. GLP-2 quickly is degraded with formation of GLP-2 (3-33). In order to extend the GLP-2 half-life, the protease-resistant analog, Gly2-GLP-2 (teduglutide) has been synthetized. The GLP-2 mainly influences gastrointestinal functions, but it exhibits also anti-inflammatory activity in intestinal disease models, in the brain of obese high fat diet (HFD) mice and can mitigate metabolic dysfunctions associated with hyperadiposity. The aim of the present study was to investigate if Gly2-GLP-2 exerts anti-inflammatory effects in AT and liver of HFD mice, which present central and peripheral IR, and to verify a possible improvement in the insulin signaling.
Baldassano S, A.A. (2020). Glucagon-like peptide-2 analog and inflammatory state in obese mice. ENDOCRINE [10.1007/s12020-020-02261-0].
File in questo prodotto:
File Dimensione Formato  
Baldassano2020_Article_Glucagon-likePeptide-2AnalogAn.pdf

Solo gestori archvio

Descrizione: Ahead of print
Tipologia: Versione Editoriale
Dimensione 561.25 kB
Formato Adobe PDF
561.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/410624
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact